Perspective Therapeutics (CATX) traded down -28.76 % during a 24 hours period ending at 01:01 AM Central Europe on Tuesday 27th. One Perspective Therapeutics stock can currently be bought for about USD 1.21 on popular exchanges. Current supply of Perspective Therapeutics stocks is 114.1 mn. Perspective Therapeutics has a current market capitalization of USD 183.8 mn and approximately USD 9 mn worth of Perspective Therapeutics was traded on exchanges in the last 24 hours. Since last month end, Perspective Therapeutics has traded -35.6 % down. Simple moving average of last 200 days is at USD 3.58. The highest price of past 52 weeks was recorded at USD 6.16 on 01/29/2026. 52 weeks low was at USD 1.58 on 10/23/2026.
Here is how related stocks have performed in the past 24 hours:
Zumiez (ZUMZ) traded down -1.81 % and now trades at USD 13.72. Current market capitalisation for Zumiez is USD 216.3 mn. Current price/earnings ratio for Zumiez is 18.29.
Op (OPBK) traded down -2 % and now trades at USD 15. Op has a market capitalisation of USD 219.8 mn. Op has a current price to earnings ratio of 7.47.
Kaltura (KLTR) traded flat 0 % and now trades at USD 1.4. Current market capitalisation for Kaltura is USD 219.7 mn.
Electromed (ELMD) traded down -1.86 % and now trades at USD 26.62. Electromed has a market capitalisation of USD 218.5 mn. Electromed has a current price to earnings ratio of 20.46.
Xai Fltng Rte&alt -Ui (XFLT) traded down -2.72 % and now trades at USD 16.46. Xai Fltng Rte&alt -Ui has a market capitalisation of USD 219.2 mn.
About Perspective Therapeutics
Perspective Therapeutics, Inc. is a biotech company that specializes in developing cesium-131 brachytherapy seeds and utilizing a proprietary technology that involves the isotope lead-212 to deliver powerful alpha radiation specifically to cancer cells via specialized targeting peptides. The company operates globally, serving customers worldwide, and their website is accessible under www.perspectivetherapeutics.com . Perspective Therapeutics trades on the NYSE MKT.